$HIMS BIG PARTNERSHIP WITH $NVO

$HIMS THIS PARTNERSHIP WITH $NVO CHANGES THE GAME. 🚨

$HIMS just inked a game-changing partnership with Novo Nordisk to offer Wegovy® directly through the Hims & Hers platform.

This isn’t just another product add-on—it’s a major move into chronic care.

Here’s why this could fuel massive growth:

⸻

Wegovy® is one of the most in-demand weight loss drugs on the market.

By bundling it with 24/7 care, clinical support, and nutrition guidance—$HIMS is now offering a complete obesity treatment solution starting at just $99/month.

⸻

This unlocks a new revenue stream in a booming market.

Obesity care is a $100B+ industry—and $HIMS is making it more affordable, more digital, and more consumer-friendly than ever before.

That’s sticky revenue with real long-term potential.

⸻

This move also helps $HIMS evolve from a telehealth brand into a chronic care platform.

That means: • Higher lifetime customer value • Lower churn • Stronger pricing power • Better margins as it scales

⸻

CEO Andrew Dudum confirmed this is just the first step in a long-term roadmap with Novo Nordisk.

That means more treatments, more care offerings, and potentially—exclusive partnerships down the line.

⸻

At just a ~$3B market cap, $HIMS is still flying under the radar.

This deal shows how serious they are about transforming healthcare access—and how big the vision really is.

⸻

$HIMS is no longer just skincare & hair loss.

It’s becoming a full-stack digital health platform tackling real problems with real solutions—and this Wegovy® deal is proof.

Watch the next few quarters closely. This story is just beginning.